TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance - Wikidata - wikimedia - TriplyDB

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

http://www.wikidata.org/entity/Q36073450

about

The Pathophysiological Role of Microglia in Dynamic Surveillance, Phagocytosis and Structural Remodeling of the Developing CNS.Young microglia restore amyloid plaque clearance of aged microglia.Increase of TREM2 during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis.TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury.The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism.Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.Absence of CX3CR1 impairs the internalization of Tau by microglia.TREM2 in Neurodegenerative Diseases.TREM2-Ligand Interactions in Health and Disease.Heterozygote galactocerebrosidase (GALC) mutants have reduced remyelination and impaired myelin debris clearance following demyelinating injury.Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes.Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment.TREM2 promotes Aβ phagocytosis by upregulating C/EBPα-dependent CD36 expression in microglia.An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function.Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy.Erythromyeloid-Derived TREM2: A Major Determinant of Alzheimer's Disease Pathology in Down Syndrome.Pericyte implantation in the brain enhances cerebral blood flow and reduces amyloid-β pathology in amyloid model mice.Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes.Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies.Heterozygous carriers of galactocerebrosidase mutations that cause Krabbe disease have impaired microglial function and defective repair of myelin damage.Innate immune activation in Alzheimer’s disease.Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup Un implant bioactif pour prévenir la maladie d’Alzheimer Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis The Trem2 R47H Alzheimer's risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans

P2860

Q33809671-B456BBD2-F5B0-4802-8FCE-79F30F4781B2 Q36231976-8CB23ED4-AF45-4780-ADFF-8B9C0D79BD4E Q36280558-15FFF249-CBD5-425D-8D83-8D1965E19646 Q36366427-BFF01387-F880-4FA3-8475-2B0630FB44E8 Q36385532-A5D4BE43-3FB0-4A73-AA6F-9456A328EA58 Q37743591-B05946D4-2A04-4619-B34A-5FEEBA94D3F6 Q38623440-54170708-4404-4D31-8472-8B6DB8AECB27 Q38646212-51B4CAA7-EF03-4D64-9FAA-74BBD8A136F9 Q38692159-569F8350-067B-4D48-BE10-792148127381 Q38748464-FF702334-D4AC-47F1-BBF0-833F728F0BD7 Q39135845-737F452F-917D-42EE-91CA-E46B55601C13 Q41173167-718A4312-31AB-4243-9DEB-D9FA1B6D39AB Q41327616-67D9ECBA-A113-413A-872C-73ABC8CDE488 Q42091243-32CB41E9-B998-49FD-B2B6-A5AC1A7F821C Q47222390-2223ADF2-1C6D-4F01-9BAB-4F206FBD4100 Q47253602-B6ED1726-9926-4DD8-A03C-F8F99BE12E20 Q47437348-DBBF48DF-961B-458A-A2AD-DCE868E9480F Q47844298-B0C333D3-42C6-47DE-A336-9B6B9FA68CEC Q50532471-C53DF67D-C653-4B1F-80AD-807224971C82 Q52330247-4AB64BF0-99D1-41A1-8CB7-B4EB1F64B310 Q55289589-3B275F6C-5EFA-4689-A39A-2F2D765D47DE Q57168893-6954E45B-6A2F-4AF8-9458-548AB83D8474 Q57982969-A09DD23A-5D43-4E83-A6BE-2C2148F69419 Q58697755-6828A320-36AF-4A55-8AD5-FF2B9DE498AE Q58762197-6119452C-4184-4AAD-9A57-0B3A20CD6436

P2860

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

http://www.wikidata.org/entity/Q36073450

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

@ast

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

@en

type

label

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

@ast

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

@en

prefLabel

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

@ast

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

@en

P1433

Q36073450-FF341DE9-007D-4AEF-86F9-C187978802F5

P1476

Q36073450-BBF8C175-A4C7-4E94-87C5-CB7BD76CAF5C

P2093

Q36073450-247E57F6-E004-4646-ABF1-A56F068D67F4

Q36073450-682F0BF1-9E97-4D2A-8139-665FB630C698

Q36073450-70AEE3CB-2567-4566-B500-708BAD1DEA33

Q36073450-77108431-DDA9-4FE2-9395-636D5B2FA53F

Q36073450-A6C34498-1F82-4372-96F3-059DB9485427

Q36073450-B39EA111-7357-4717-8CC0-E82E97BF4278

P2860

Q36073450-02B902A4-A809-43AD-B48A-28F3913F780F

Q36073450-03061A96-A4F4-4828-A5F6-9639071DC392

Q36073450-048A7A2B-9A1E-4F63-A201-EE62BB3D2C63

Q36073450-083C455A-85A0-45E3-A7FC-2D5EFBC766D4

Q36073450-09051DE7-F660-4E25-ADFF-FE71DD297887

Q36073450-11B55548-E8ED-4CA2-8E85-99519DF2F08D

Q36073450-15B74304-7A3B-4533-842B-087B5C3188CA

Q36073450-2F263053-76FE-4AE7-AEA8-0E96DA0EB4FC

Q36073450-302DAF9A-8586-4063-8E01-5AFC3FFB87EE

Q36073450-317E7C48-2885-4710-9D2B-94962ED59CFF

P304

Q36073450-884C8BB4-2AE2-4112-A62C-92D36A1C515C

P31

Q36073450-4C17E2D0-B98B-4F6E-B514-34A41C925187

P356

Q36073450-31AA163B-AC37-4487-82C3-BA236F51A6C8

P433

Q36073450-1DAE8B40-4664-4D9D-B8B3-FFF50B88E65E

P478

Q36073450-ACB40EAD-F7CA-45BF-A979-DA1B7B790C86

P50

Q36073450-40F85AAD-888A-40AA-B280-C03F45530168

Q36073450-46EAD595-E0E3-4D92-BAB6-706EA111E332

Q36073450-5AFC748C-6E40-43A6-B7C2-B2541D860BB2

Q36073450-BA525CC7-B0D0-4A4A-9233-EC86C38236F4

P577

Q36073450-B58E3BF4-A916-4282-85F6-825A2724106D

P698

Q36073450-5C3E8044-FB6B-4511-A326-C22F1C730B1C

P921

Q36073450-4F3826D1-A583-40A3-86D2-254919A87B56

P932

Q36073450-1FBA3E05-72D6-4556-89D0-739F6E3F30F0

P356

P1433

EMBO Molecular Medicine

P1476

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

@en

P2093

Arthur Liesz

http://www.w3.org/2001/XMLSchema#string

Bernd Bohrmann

http://www.w3.org/2001/XMLSchema#string

Fargol Mazaheri

http://www.w3.org/2001/XMLSchema#string

Georg Werner

http://www.w3.org/2001/XMLSchema#string

Irene Knuesel

http://www.w3.org/2001/XMLSchema#string

Regina Feederle

http://www.w3.org/2001/XMLSchema#string

P2860

Genome engineering using the CRISPR-Cas9 system

TREM2 Variants in Alzheimer's Disease

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

NIH Image to ImageJ: 25 years of image analysis

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Immunotherapeutic approaches for Alzheimer's disease

Control of peripheral nerve myelination by the beta-secretase BACE1

A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

P304

992-1004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15252/EMMM.201606370

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Christian Haass

Gernot Kleinberger

P577

2016-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27402340

http://www.w3.org/2001/XMLSchema#string

P921

P932

5009806

http://www.w3.org/2001/XMLSchema#string